Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background/Aims: Glucagon-like peptide-1 receptor agonist liraglutide has been reported to exert cardioprotective effects, but its effect on cardiac fibrosis remains controversial. The aim of this study was to investigate the effects of liraglutide on cardiac fibrosis and potential mechanisms. Methods: C57BL/6 mice (3-month old) were randomly divided into control, hypertension, and hypertension + liraglutide groups. The hypertensive state was created by infusion of Ang II (100 ng/kg·min) for 4 weeks through subcutaneously implanted osmotic pumps. The control mice were infused with saline. Mice were also given vehicle or liraglutide (400 μg/kg·day). Blood pressure (BP), blood sugar, myocardial fibrosis, AT1R expression, and reactive oxygen species (ROS) levels were measured. To further elucidate the mechanisms of fibrosis, mouse cardiac fibroblasts were isolated and treated with liraglutide (300 nM/L) or losartan (10 μM) for 3 hours, followed by Ang II (10 −7 M) for additional 12 hours. Reactive oxygen species production and expressions of collagen-1 and -3 were measured. Results: Liraglutide reduced BP and blood sugar but did not affect the body weight of the hypertensive mice. Liraglutide also inhibited collagen accumulation, AT1R expression, and ROS generation in the hearts of the hypertensive mice. In in vitro studies, pretreatment with liraglutide and losartan (as control) markedly inhibited Ang II-induced ROS production and collagen expression in the cultured cardiac fibroblasts. Conclusion: Liraglutide reduces myocardial fibrosis in the hypertensive mice, which appears to be dependent on at least in part inhibition of ROS production.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, they may mitigate cardiac fibroblast development and myocardial fibrosis by modulating the CD36-JNK-AP1 pathway, which reduces P4HA1 levels, blocking ROS production mediated by the Ang II type I receptor.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [49]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“More importantly, clinical trials also indicated that liraglutide did not reduce the rates of nonfatal myocardial infarction and hospitalizations for heart failure.(17) It is possible that the species specificity may be one of the main factors behind the controversy.”
BackgroundGlobal Public Health Burden of Heart Failure
Savarese, G., Lund, L. H., Division of Cardiology, D. O. M., Department of Cardiology, K. U. H., Division of Cardiology, D. O. M., & Department of Cardiology, K. U. H. (2017) · Cardiac Failure Review · doi:10.15420/cfr.2016:25:2 · Cited by 2,641 · cited 1×
“Heart failure is a major health problem affecting 20 to 30 million people around the world.(1) Myocardial fibrosis, the excess deposition of extracellular matrix in the ventricular wall, is a hallmark of mid- to late-stage heart failure, which occurs in long-standing hypertension.”
BackgroundCardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration
Talman, V., & Ruskoaho, H. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2431-9 · Cited by 905
Myocardial Interstitial Fibrosis in Heart Failure
González, A., Schelbert, E. B., Díez, J., & Butler, J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.021 · Cited by 660 · cited 2×
“Myocardial fibrosis, the excess deposition of extracellular matrix in the ventricular wall, is a hallmark of mid- to late-stage heart failure, which occurs in long-standing hypertension.(2) The persistent pressure overload causes excessive accumulation of collagens, mainly collagen type I and type III fibers, in the i…”
BackgroundThe origin of fibroblasts and mechanism of cardiac fibrosis
Krenning, G., Zeisberg, E. M., & Kalluri, R. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22322 · Cited by 601 · cited 1×
“The abnormal secretion of collagen from cardiac fibroblasts is thought to be the basis of cardiac fibrosis.(29) It is known that both hypertension and diabetes are independent risk factors for Figure 6.”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 2×
“Some studies showed that liraglutide exerts cardioprotective effects in animal and clinical studies.(15,16) Bizino et al reported that liraglutide could reduce the infarct volume and slow the progression of diabetic cardiomyopathy in patients with type 2 diabetes.”
BackgroundRusso, I., & Frangogiannis, N. G. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.011 · Cited by 474
The Cardiac Renin-Angiotensin System: Conceptual, or a Regulator of Cardiac Function?
Dostal, D. E., & Baker, K. M. (1999) · Circulation Research · doi:10.1161/01.res.85.7.643 · Cited by 398 · cited 2×
“The activation of renin-angiotensin system (RAS) and subsequent release of Ang II is thought to play a role in the development of hypertension and myocardial fibrosis via stimulation of AT1R.(4,5) Development of fibrosis, which leads to a progressive increase of ventricular stiffness and impaired diastolic function, i…”
BackgroundLim, D.-S., Lutucuta, S., Bachireddy, P., Youker, K., Evans, A., Entman, M., Roberts, R., & Marian, A. J. (2001) · Circulation · doi:10.1161/01.cir.103.6.789 · Cited by 386 · cited 1×
“Losartan effectively reverses myocardial fibrosis in the murine hypertensive models.(37,38) Based on the similarity of actions of losartan and liraglutide, it may be concluded that liraglutide acts as an anti-fibrosis drug works in part by inhibiting AT1R-ROS axis.”
BackgroundCardiac fibrosis: new insights into the pathogenesis
Ma, Z.-G., Yuan, Y.-P., Wu, H.-M., Zhang, X., & Tang, Q.-Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.28103 · Cited by 331 · cited 1×
“Despite the high prevalence of diastolic heart failure, there are currently no effective remedies to control or inhibit cardiac fibrosis and improve the clinical state.(9) Glucagon-like peptide 1 (GLP-1) is an incretin hormone that enhances insulin secretion through adenylyl cyclase, inhibits glucagon secretion, delay…”
BackgroundLiu, Z., & Habener, J. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706105200 · Cited by 326
Noyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259
Myocardial remodeling in hypertension
Nadruz, W. (2015) · Journal of Human Hypertension · doi:10.1038/jhh.2014.36 · Cited by 258 · cited 1×
“The persistent pressure overload causes excessive accumulation of collagens, mainly collagen type I and type III fibers, in the interstitium and the perivascular tissues of the heart.(3) The activation of renin-angiotensin system (RAS) and subsequent release of Ang II is thought to play a role in the development of hy…”
BackgroundInflammation, Autophagy, and Apoptosis After Myocardial Infarction
Wang, X., Guo, Z., Ding, Z., & Mehta, J. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008024 · Cited by 243
Self-citationChronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension
Grobe, J. L., Mecca, A. P., Mao, H., & Katovich, M. J. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01170.2005 · Cited by 222 · cited 5×
“Ang II is a major component of RAS, which stimulates collagen synthesis and secretion from fibroblasts and myofibroblasts through activating its type 1 receptor (AT1R).34 In accordance with previous reports, we observed an increase in AT1R expression (immunostaining and Western blotting) and ROS production in the mous…”
BackgroundInfluentialNagata, D., Takeda, R., Sata, M., Satonaka, H., Suzuki, E., Nagano, T., & Hirata, Y. (2004) · Circulation · doi:10.1161/01.cir.0000136025.96811.76 · Cited by 198
Angiotensin II receptors and drug discovery in cardiovascular disease
Dasgupta, C., & Zhang, L. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.016 · Cited by 173 · cited 1×
“Indeed, AT1R-mediated ROS production in cardiovascular system and its relevance have been recently discussed.(36) As control for liraglutide, we used a specific AT1R blocker losartan and showed that it prevented ROS generation and collagen-1 and -3 expressions.”
Bizino, M. B., Jazet, I. M., Westenberg, J. J. M., van Eyk, H. J., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0857-6 · Cited by 137 · cited 2×
“Bizino et al reported that liraglutide could reduce the infarct volume and slow the progression of diabetic cardiomyopathy in patients with type 2 diabetes.(15) Noyan Ashraf et al reported that liraglutide not only reduced cardiac rupture and infarct size but also improved cardiac output.”
BackgroundSkov, J., Pedersen, M., Holst, J. J., Madsen, B., Goetze, J. P., Rittig, S., Jonassen, T., Frøkiær, J., Dejgaard, A., & Christiansen, J. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12651 · Cited by 128 · cited 1×
“In addition, liraglutide has been reported to decrease the plasma level of Ang II in patients with type 2 diabetes.(22) Wang et al(23) showed that pretreatment with liraglutide protected myocytes from injury, reduced myocardial infarct size, improved cardiac function, and inhibited collagen synthesis in the mouse hear…”
BackgroundThe Aging Heart, Myocardial Fibrosis, and its Relationship to Circulating C-Type Natriuretic Peptide
Sangaralingham, S. J., Huntley, B. K., Martin, F. L., McKie, P. M., Bellavia, D., Ichiki, T., Harders, G. E., Chen, H. H., & Burnett, J. C. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.160796 · Cited by 117
Reimer, R. A. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06557 · Cited by 112
Salehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108 · cited 1×
“Glucagon-like peptide 1 (GLP-1) is an incretin hormone that enhances insulin secretion through adenylyl cyclase, inhibits glucagon secretion, delays gastric emptying, and reduces postprandial hyperglycemia.(10,11) Glucagon-like peptide 1 binding to its receptor (GLP-1-R), a G protein-coupled receptor in pancreatic b c…”
BackgroundSpurney, C. F., Sali, A., Guerron, A. D., Iantorno, M., Yu, Q., Gordish‐Dressman, H., Rayavarapu, S., van der Meulen, J., Hoffman, E. P., & Nagaraju, K. (2011) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248410381757 · Cited by 108 · cited 1×
“Losartan effectively reverses myocardial fibrosis in the murine hypertensive models.(37,38) Based on the similarity of actions of losartan and liraglutide, it may be concluded that liraglutide acts as an anti-fibrosis drug works in part by inhibiting AT1R-ROS axis.”
BackgroundSeccia, T. M., Belloni, A. S., Kreutz, R. H., Paul, M., Nussdorfer, G. G., Pessina, A. C., & Rossi, G. P. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02860-7 · Cited by 104 · cited 4×
“It is a common problem associated with nearly all forms of heart disease and believed to be the final pathway causing heart failure.2 The abnormal secretion of collagen from cardiac fibroblasts is thought to be the basis of cardiac fibrosis.29 It is known that both hypertension and diabetes are independent risk factor…”
BackgroundInfluentialDíaz-Araya, G., Vivar, R., Humeres, C. D., Boza, P., Bolívar, S., & Muñoz, C. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.001 · Cited by 91 · cited 1×
“Ang II is a major component of RAS, which stimulates collagen synthesis and secretion from fibroblasts and myofibroblasts through activating its type 1 receptor (AT1R).(34) In accordance with previous reports, we observed an increase in AT1R expression (immunostaining and Western blotting) and ROS production in the mo…”
BackgroundThe role of AMP-activated protein kinase in the cardiovascular system
Nagata, D., & Hirata, Y. (2009) · Hypertension Research · doi:10.1038/hr.2009.187 · Cited by 86 · cited 1×
“It has been reported that AMPKa signaling exerts a direct inhibitory effect on ATR1 both in terms of the receptor’s expression and signaling.(43,44) Liraglutide also inhibits cardiac remodeling via regulating PI3K/Akt1 and AMPKa signaling.”
BackgroundHu, C.-P., Dandapat, A., Sun, L., Marwali, M. R., Inoue, N., Sugawara, F., Inoue, K., Kawase, Y., Jishage, K., Suzuki, H., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.115287 · Cited by 85
Self-citationLi, H., Zhao, X.-Z., Zhang, X., Li, G., Jia, Z., Sun, P., Wang, J.-Q., Fan, Z., & Lv, G. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9327-7 · Cited by 84
Zhang, L., Pang, X.-F., Bai, F., Wang, N.-P., Shah, A., McKallip, R. J., Li, X., Wang, X., & Zhao, Z. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6592-7 · Cited by 84 · cited 1×
“Zhang et al showed that liraglutide can inhibit collagen-I synthesis and cardiac fibrosis in rats through a reduction in the ratio of AT1/AT2 receptor expression and increasing angiotensin-converting enzyme 2 (ACE2) activity.(20) Fandiño et al also observed that liraglutide could increase ACE2 expression in rats with…”
BackgroundSelf-citationDiabetes-Related Heart Failure: Does Diabetic Cardiomyopathy Exist?
Bando, Y., & Murohara, T. (2014) · Circulation Journal · doi:10.1253/circj.cj-13-1564 · Cited by 83 · cited 1×
“Prevention of cardiac fibrosis is an essential goal in the management of hypertensive heart disease, which is often associated with diabetes.(31,32) Liraglutide, a long-acting GLP-1-R agonist has been reported to prevent myocardial fibrosis in patients and in some animal models of diabetes and myocardial infarction(18…”
BackgroundPathophysiology and therapeutic potential of cardiac fibrosis
Hara, H., Takeda, N., & Komuro, I. (2017) · Inflammation and Regeneration · doi:10.1186/s41232-017-0046-5 · Cited by 75 · cited 1×
“In the pathological state, cardiac fibroblasts proliferate, become activated in response to neurohormonal changes such as heightened levels of Ang II, and produce collagen.(40) Our previous study showed that liraglutide could attenuate Ang II- and glucose-induced collagen formation in isolated cultured cardiac fibrobl…”
BackgroundKristensen, J., Mortensen, U. M., Schmidt, M., Nielsen, P. H., Nielsen, T. T., & Maeng, M. (2009) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-9-31 · Cited by 71 · cited 2×
“Although several studies(16,42,41) showed cardioprotective effect of liraglutide in mice or in vitro experiments, other studies suggest that liraglutide may not exert cardioprotection in large animal models.(46,47) For instance, Kristensen et al and Mortensen et al both showed that administration of liraglutide did no…”
BackgroundBai, F., Pang, X.-F., Zhang, L., Wang, N.-P., McKallip, R. J., Garner, R. E., & Zhao, Z. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.04.013 · Cited by 50 · cited 2×
“The activation of renin-angiotensin system (RAS) and subsequent release of Ang II is thought to play a role in the development of hypertension and myocardial fibrosis via stimulation of AT1R.(4,5) Development of fibrosis, which leads to a progressive increase of ventricular stiffness and impaired diastolic function, i…”
BackgroundZheng, R.-H., Bai, X.-J., Zhang, W.-W., Wang, J., Bai, F., Yan, C.-P., James, E., Bose, H., Wang, N.-P., & Zhao, Z.-Q. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s213910 · Cited by 50 · cited 2×
“Actually, a recent study reported liraglutide and telmisartan (another AT1 blocker) both markedly improved cardiac performance of hypertensive rats.(35) Cardiac fibroblasts account for approximately 25% of myocardial volume and 60% of all cells in the heart in the physiologic state.”
BackgroundGaspari, T., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 49 · cited 2×
“Gaspari et al also observed that liraglutide suppressed cardiac fibrosis through inhibiting NF-kB expression and activity in obesity, hypertension, and age-induced murine models.(19) Despite advances in understanding the mechanisms of cardioprotective effects of liraglutide, its role in preventing cardiac fibrosis rem…”
BackgroundEffect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Zhao, X., Huang, K., Zheng, M., & Duan, J. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0332-5 · Cited by 49 · cited 1×
“A recent study suggested BPlowering effect of liraglutide in individuals, which is dependent on drug dose.(48) We believe that the reduction in BP as well as lowering of blood sugar may be the physiologic mediators of the anti-fibrotic effect of liraglutide.”
BackgroundFandiño, J., Vaz, A. A., Toba, L., Romaní-Pérez, M., González-Matías, L., Mallo, F., & Diz-Chaves, Y. (2018) · International Journal of Endocrinology · doi:10.1155/2018/6920620 · Cited by 39 · cited 1×
“Fandiño et al also observed that liraglutide could increase ACE2 expression in rats with food restriction but did not affect ACE1 expression.(21) In addition, liraglutide has been reported to decrease the plasma level of Ang II in patients with type 2 diabetes.”
BackgroundWang, X., Lü, J., Khaidakov, M., Mitra, S., Ding, Z., Raina, S., Goyal, T., & Mehta, J. L. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.01.013 · Cited by 33
Self-citationWang, X., Ding, Z., Yang, F., Dai, Y., Chen, P., Theus, S. A., Singh, S. P., Budhiraja, M., & Mehta, J. L. (2016) · Clinical Science · doi:10.1042/cs20160061 · Cited by 33 · cited 2×
“production and inflammatory cytokines in the hearts following myocardial infarction.(23) An in vitro study indicated that liraglutide protected against cardiomyocyte injury induced by H2O2 by preserving physiological levels of calcium.”
BackgroundMethodSelf-citationLiu, S., Duan, X., Jin, S., Teng, X., Xiao, L., Xue, H., & Wu, Y. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw104 · Cited by 33 · cited 1×
“Previous studies have shown increased AT1R expression and reactive oxygen species (ROS) generation in the hypertensive murine hearts.(27,28) In accordance with these reports, we observed an increase of AT1R expression (Figure 3) and ROS production in the mouse hearts following 4-week of Ang II infusion (Figure 4).”
BackgroundOwens, D. R., Monnier, L., & Hanefeld, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12998 · Cited by 31 · cited 1×
“Glucagon-like peptide 1 (GLP-1) is an incretin hormone that enhances insulin secretion through adenylyl cyclase, inhibits glucagon secretion, delays gastric emptying, and reduces postprandial hyperglycemia.(10,11) Glucagon-like peptide 1 binding to its receptor (GLP-1-R), a G protein-coupled receptor in pancreatic b c…”
BackgroundHuang, D.-D., Hf, H., Yang, Q., & Chen, X. (2018) · PubMed · doi:10.26355/eurrev_201807_15524 · Cited by 30 · cited 1×
“Some studies have shown that liraglutide has the potential to suppress cardiac fibrosis under a series of pathological conditions.(18,19) Zhang et al showed that liraglutide can inhibit collagen-I synthesis and cardiac fibrosis in rats through a reduction in the ratio of AT1/AT2 receptor expression and increasing angi…”
BackgroundWang, X., Zhang, F., Yang, F., Ding, Z., Agarwal, N., Guo, Z., & Mehta, J. L. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.72 · Cited by 26 · cited 2×
“Our previous study showed that liraglutide could attenuate Ang II- and glucose-induced collagen formation in isolated cultured cardiac fibroblasts by inhibiting ERK1/2 and nuclear factor kB (NF-kB) pathways.(24) Gaspari et al also observed that liraglutide suppressed cardiac fibrosis through inhibiting NF-kB expressio…”
BackgroundSelf-citationLOX-1 in the maintenance of cytoskeleton and proliferation in senescent cardiac fibroblasts
Wang, X., Khaidakov, M., Ding, Z., Dai, Y., Mercanti, F., & Mehta, J. L. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.04.024 · Cited by 21 · cited 1×
“Cardiac fibroblasts account for approximately 25% of myocardial volume and 60% of all cells in the heart in the physiologic state.(39) In the pathological state, cardiac fibroblasts proliferate, become activated in response to neurohormonal changes such as heightened levels of Ang II, and produce collagen.”
BackgroundSelf-citationKyhl, K., Lønborg, J., Hartmann, B., Kissow, H., Poulsen, S. S., Ali, H. H. E., Kjær, A., Dela, F., Engstrøm, T., & Treiman, M. (2017) · Peptides · doi:10.1016/j.peptides.2017.04.009 · Cited by 17 · cited 1×
“Liraglutide, a long-acting GLP-1-R agonist has been reported to prevent myocardial fibrosis in patients and in some animal models of diabetes and myocardial infarction(18,19) but not in all.(33) In the present study, we asked if liraglutide would reduce cardiac fibrosis in hypertensive mice.”
BackgroundEffects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs*
Ekström, K., Dalsgaard, M., Iversen, K. K., Pedersen‐Bjergaard, U., Vejlstrup, N., Diemar, S. S., Idorn, M., Thorsteinsson, B., & Engstrøm, T. (2016) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2016.1197417 · Cited by 13 · cited 2×
“Although several studies(16,42,41) showed cardioprotective effect of liraglutide in mice or in vitro experiments, other studies suggest that liraglutide may not exert cardioprotection in large animal models.(46,47) For instance, Kristensen et al and Mortensen et al both showed that administration of liraglutide did no…”
BackgroundPalee, S., Chattipakorn, S. C., & Chattipakorn, N. (2017) · Physiological Research · doi:10.33549/physiolres.933558 · Cited by 11 · cited 1×
“An in vitro study indicated that liraglutide protected against cardiomyocyte injury induced by H2O2 by preserving physiological levels of calcium.(42) This study also suggested that liraglutide prevented cardiac fibrosis in hypertensive mice in part by inhibiting AT1R-ROS pathway.”
Background
Research works printed but not linked: 2
- Huang DD, 2018, Eur Rev Med Pharmacol Sci, 22, 4648
- Li R, 2019, Front Pharmacol, 10, 10537
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
“For example, GLP-1RAs may modulate the CD36-JNK-AP1 pathway by partially down-regulating prolyl 4-hydroxylase subunit alpha-1 (P4HA1), and then inhibit ROS production mediated by Ang II type I receptor, thereby ameliorating cardiac fibroblast proliferation and myocardial fibrosis [167, 168].”
BackgroundKhavinson, V., Linkova, N. S., Dyatlova, A., Кантемирова, Р. К., & Kozlov, K. L. (2022) · Cells · doi:10.3390/cells12010106 · Cited by 88
Diabetes and Myocardial Fibrosis
Salvador, D., Gamba, M., González-Jaramillo, N., González-Jaramillo, V., Raguindin, P. F., Minder, B., Gräni, C., Wilhelm, M., Stettler, C., Doria, A., et al. (2022) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.12.008 · Cited by 72
Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
Ghosh, P., Fontanella, R. A., Scisciola, L., Pesapane, A., Taktaz, F., Franzese, M., Puocci, A., Ceriello, A., Prattichizzo, F., Rizzo, M. R., et al. (2023) · Theranostics · doi:10.7150/thno.86831 · Cited by 73
“2020 [122] C57BL/6 mice Cardiac fibroblasts Liraglutide Inhibition of Ang II-AT1R-ROS Reactive oxygen”
Background
Metadata
- Authors
- Chen, P., Yang, F., Wang, W., Li, X., Liu, D., Zhang, Y., Yin, G., Lv, F., Guo, Z., Mehta, J. L., & Wang, X.
- Affiliations
- Zhengzhou University (CN)
- Henan Medical University (CN)
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Central Arkansas Veterans Healthcare System (US)
- Corresponding author
- Mehta, Jawahar L.
- Wang, Xianwei
- ORCID
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2020-07-20
- Volume
- 26
- Issue
- 2
- Pages
- 179-188
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- OpenAlex
- W3044882533
- Cited by
- 31
- References
- 47
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 5
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Cardiovascular Pharmacology and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (U1804166 and 81873459)
- henan university (19HASTIT004)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liraglutide, myocardial fibrosis, angiotensin II, angiotensin II type 1 receptor, reactive oxygen species, hypertension, GLP-1 receptor agonists, cardiac fibroblasts, collagen expression, losartan, cardioprotection
- MeSH terms
- Liraglutide, Animals, Fibrosis, Heart, Hypertension, Male, Mice, Inbred C57BL, Myocardium, Reactive Oxygen Species, Receptor, Angiotensin, Type 1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.